Trevi Therapeutics, Inc. TRVI
14.33 USD +1.52 (+11.87%)
At closeNov 6, 2026, 4:00 PM EST
14.90 +0.57 +3.98%
After hours · Nov 6, 4:00 PM ET
13.00 Day range 14.36
9.82 52-week range 20.22
- YTD
- +14.46%
- 1 year
- +30.15%
News
globenewswire.com Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026 NEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral…
benzinga.com Trevi Therapeutics Announces Results From Phase 2b CORAL Trial Accepted As Oral Presentation At CHEST 2026 Annual Meeting Of American College Of Chest Physicians Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with…
benzinga.com Trevi Therapeutics Q2 2026 Earnings Call Transcript Trevi Therapeutics (NASDAQ:TRVI) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For…